CERo Therapeutics jumps on US FDA's 'fast track' tag for cancer therapy
Shares of drug developer CERo Therapeutics CERO.O rise 11% to $7.65 premarket
Co says its experimental blood cancer therapy, CER-1236, received U.S. FDA's "fast track" tag
FDA's "fast track" tag aims to speed development and review of drugs for serious conditions with unmet medical need
The therapy is being tested in an early stage trial for patients with aggressive forms of acute myeloid leukemia, a type of blood and bone marrow cancer
Stock down 94% YTD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Citi Raises Brent Crude Forecast to $150: Strait of Hormuz Risks Brew, How High Can Oil Prices Rise?

Fed FOMC Preview: No Rate Cuts Become Consensus, Warsh Succession Imminent

Marvell vs. Broadcom: Who Is the More Worthy ASIC Leading Company?

Tesla Stock Forecast: How Much Will TSLA Stock Be Worth in 2030? Can It Hit $3,000?

SanDisk Earnings Preview: AI Storage Drives Performance Surge, Valuations and Risks Rise

Tradingkey






